Metabasis Therapeutics , Inc.

Metabasis Therapeutics, Inc. (www.mbasis.com) is a privately held, biopharmaceutical company that develops proprietary products for the treatment of human disease with a current focus on liver and liver-related diseases. The Company employs various resources for discovering and perfecting new products, is a leader in the field of nucleoside/nucleotide chemistry and metabolism, and has proprietary expertise in liver biology and liver-specific drug delivery. Metabasis has discovered and developed a new class of drugs for treating diabetes that act to lower liver glucose production in diabetic patients. The first drug from this program, CS-917, is being developed in collaboration with Sankyo Co., Ltd. and is currently undergoing clinical ( www.mbasis.com )